Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5643875A · kind A · utility
19Cited by
7References
12Claims
0Family size
Inventors
Key dates
| Filing date | Aug 16, 1994 |
| Grant date | Jul 1, 1997 |
| Priority date | — |
| Expiry date | Aug 16, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/83
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.